13,177 Shares in Stryker Co. (NYSE:SYK) Purchased by Cullen Investment Group LTD.

Cullen Investment Group LTD. bought a new stake in Stryker Co. (NYSE:SYK - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 13,177 shares of the medical technology company's stock, valued at approximately $3,946,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Keybank National Association OH grew its position in shares of Stryker by 3.5% in the third quarter. Keybank National Association OH now owns 27,823 shares of the medical technology company's stock valued at $7,603,000 after purchasing an additional 952 shares during the last quarter. Carnegie Capital Asset Management LLC grew its position in shares of Stryker by 0.5% in the fourth quarter. Carnegie Capital Asset Management LLC now owns 96,241 shares of the medical technology company's stock valued at $28,820,000 after purchasing an additional 497 shares during the last quarter. CoreCap Advisors LLC grew its position in Stryker by 3.9% during the fourth quarter. CoreCap Advisors LLC now owns 5,030 shares of the medical technology company's stock worth $1,506,000 after buying an additional 191 shares in the last quarter. DNB Asset Management AS grew its position in Stryker by 5.7% during the fourth quarter. DNB Asset Management AS now owns 76,413 shares of the medical technology company's stock worth $22,883,000 after buying an additional 4,143 shares in the last quarter. Finally, LGT Capital Partners LTD. grew its position in Stryker by 24.4% during the fourth quarter. LGT Capital Partners LTD. now owns 434,997 shares of the medical technology company's stock worth $130,264,000 after buying an additional 85,240 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company's stock.

Stryker Trading Down 0.9 %

NYSE:SYK traded down $2.92 during trading hours on Monday, hitting $339.13. 1,010,142 shares of the company were exchanged, compared to its average volume of 1,255,121. The stock has a market capitalization of $129.03 billion, a price-to-earnings ratio of 41.07, a price-to-earnings-growth ratio of 2.75 and a beta of 0.89. The company has a current ratio of 1.58, a quick ratio of 0.97 and a debt-to-equity ratio of 0.59. Stryker Co. has a one year low of $249.98 and a one year high of $361.41. The company has a fifty day simple moving average of $350.82 and a 200 day simple moving average of $310.95.

Stryker (NYSE:SYK - Get Free Report) last announced its earnings results on Tuesday, January 30th. The medical technology company reported $3.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.27 by $0.19. The business had revenue of $5.82 billion during the quarter, compared to analyst estimates of $5.60 billion. Stryker had a return on equity of 22.99% and a net margin of 15.44%. Stryker's revenue for the quarter was up 11.8% compared to the same quarter last year. During the same period last year, the company earned $3.00 EPS. Sell-side analysts expect that Stryker Co. will post 11.86 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be given a dividend of $0.80 per share. This represents a $3.20 annualized dividend and a yield of 0.94%. The ex-dividend date of this dividend is Wednesday, March 27th. Stryker's dividend payout ratio is currently 38.79%.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on SYK. Truist Financial increased their price target on Stryker from $330.00 to $345.00 and gave the stock a "hold" rating in a research report on Wednesday, January 31st. Roth Mkm increased their price target on Stryker from $345.00 to $348.00 and gave the stock a "buy" rating in a research report on Wednesday, January 31st. Wells Fargo & Company increased their price target on Stryker from $336.00 to $364.00 and gave the stock an "overweight" rating in a research report on Wednesday, January 31st. StockNews.com raised Stryker from a "hold" rating to a "buy" rating in a research report on Tuesday, January 23rd. Finally, Canaccord Genuity Group raised Stryker from a "hold" rating to a "buy" rating and set a $360.00 target price on the stock in a report on Wednesday, January 31st. Three investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $339.22.

Insider Buying and Selling

In other news, Director Allan C. Golston sold 3,273 shares of Stryker stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $341.00, for a total value of $1,116,093.00. Following the completion of the transaction, the director now directly owns 14,242 shares of the company's stock, valued at approximately $4,856,522. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, Director Allan C. Golston sold 3,273 shares of Stryker stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $341.00, for a total value of $1,116,093.00. Following the completion of the transaction, the director now directly owns 14,242 shares of the company's stock, valued at approximately $4,856,522. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Ronda E. Stryker sold 201,146 shares of Stryker stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $342.90, for a total value of $68,972,963.40. Following the completion of the transaction, the director now directly owns 3,755,128 shares of the company's stock, valued at $1,287,633,391.20. The disclosure for this sale can be found here. Insiders sold a total of 212,109 shares of company stock valued at $72,845,768 in the last three months. Insiders own 5.50% of the company's stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.